Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J SCHAAF

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
The AAPS Journal|July 18, 2020
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and RatsZhiliang Xie, Min Chen, Swagata Goswami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Inherited Metabolic Disease|September 16, 2022
Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolismRodrigo Canibano-Fraile, Laurike Harlaar, Carlos A Dos Santos, et al.
Blood|November 5, 2008
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaMitch A Phelps, Thomas S Lin, Amy J Johnson, et al.
Blood|September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd, Thomas S Lin, James T Dalton, et al.
Circulation. Cardiovascular Genetics|January 21, 2016
Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe DiseaseStephan C A Wens, Gerben J Schaaf, Michelle Michels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancerM L Rothenberg, J R Eckardt, J G Kuhn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeksM L Rothenberg, J G Kuhn, L J Schaaf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
The AAPS Journal|July 18, 2020
Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and RatsZhiliang Xie, Min Chen, Swagata Goswami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumorsR L Drengler, J G Kuhn, L J Schaaf, et al.
Journal of Inherited Metabolic Disease|September 16, 2022
Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolismRodrigo Canibano-Fraile, Laurike Harlaar, Carlos A Dos Santos, et al.
Blood|November 5, 2008
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaMitch A Phelps, Thomas S Lin, Amy J Johnson, et al.
Blood|September 28, 2006
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd, Thomas S Lin, James T Dalton, et al.
Circulation. Cardiovascular Genetics|January 21, 2016
Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe DiseaseStephan C A Wens, Gerben J Schaaf, Michelle Michels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin, Amy S Ruppert, Amy J Johnson, et al.
Pageof 10